Status:
RECRUITING
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborating Sponsors:
Jining Medical University
The Second People's Hospital of Huai'an
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve remission rate of patients following to VA regimen treatment failure.
Detailed Description
Venetoclax and azacitidine has become the standard first-line treatment for elderly/unsuitable AML patients who can't tolerate for intense chemotherapy. However, a proportion of patients who were not...
Eligibility Criteria
Inclusion
- Patients with AML who are not suitable for intensive chemotherapy according to the WHO diagnosis: age ≥60 years or age \<60 years but fulfil the following criteria;
- Age 18 to 59 years;
- Eastern Cooperative Oncology Group (ECOG) physical status score of 2 or 3;
- Expected survival time ≥3 months;
- Or fulfilment of severe cardiac, pulmonary, hepatic, or renal disease; (A) Presence of a cardiac history of congestive heart failure, or ejection fraction ≤ 50%, or presence of chronic stable angina; (B) Lung carbon monoxide diffusing capacity (DLCO) ≤ 65%, or first forced expiratory volume (FEV1) ≤ 65%; (C) Moderate hepatic impairment with total bilirubin \> 1.5 to ≤ 3.0 x upper limit of normal (ULN); (D) Creatinine clearance ≥ 30 mL/min to \< 45 mL/min;
- Not received radiotherapy, treatment regimens other than the VA regimen, or haematopoietic stem cell transplantation within 4 weeks prior to enrolment;
- Other comorbidities that, in the judgement of the physician, make the administration of intensive chemotherapy unsuitable;
- Ability to understand and willingness to sign the informed consent for this trial;
- The patient refuses intensive chemotherapy and has the willingness to accept non-intensive chemotherapy.
Exclusion
- Patients with a history of myeloproliferative neoplasms (MPN), including myelofibrosis, thrombocythemia, polycythaemia vera, chronic granulocytic leukemia (CML) with or without BCR-ABL1 translocation, and AML or acute promyelocytic leukemia (APL) with BCR-ABL1 translocation;
- Patients with FLT3 mutations and who were treated with targeted agents (inclusion is possible if the use of specific targeted agents is discontinued);
- Patients with less than 50% reduction of blasts after VA regimen;
- Patients with active CNS involvement;
- With prior treatment with chidamide;
- Clinically uncontrolled active infections (including bacterial, fungal or viral infections) and organ hemorrhage;
- Pregnant or lactating women;
- Participation in any other clinical trial within 3 months prior to VAC regimen;
- With other malignant tumours;
- With uncontrolled mental disorders;
- Any other condition that, in the opinion of the investigator, makes it inappropriate to participate in this trial.
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06220162
Start Date
February 1 2024
End Date
December 1 2026
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006